Over the last five years, neoadjuvant/adjuvant pembrolizumab combinations have improved pathologic complete response and event-free survival in early TNBC [32]; PD-1 blockade (e.g., pembrolizumab) has improved outcomes in PD-L1-positive metastatic disease [33]; adjuvant olaparib has conferred overall-survival benefit in gBRCA-mutated, HER2-negative high-risk breast cancer [34]; and the TROP-2-targeting antibody–drug conjugate sacituzumab govitecan has become a standard in pretreated metastatic TNBC [35]. This evidence concerns the gene ERBB2 and breast carcinoma.